14 Aug 2024
We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...
21 Jun 2024
The US Food and Drug Adminisatration has announced it has expanded the approval of Sarepta Therapeutics’ gene therapy, known as Elevidys, for the treatment of ambulatory and non-ambulatory people with Duchenne aged 4 and over. In June last year we shared that...
14 Jun 2024
Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints. Click here to read Pfizer’s update on Phase 3 of CIFFREO, a randomised double-blind placebo-controlled study in ambulatory boys aged 4-7. The primary...
12 Jan 2024
The Duchenne Reserach Fund is delighted to share that the MHRA (Medicines and Healthcare products Regulatory Agency) has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. This is a significant...
18 Dec 2023
The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...
1 Nov 2023
Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne. The trial did not meet its primary endpoint: showing a difference in a change on the North Star Ambulatory Assessment (NSAA) total score – which...
28 Oct 2023
The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...
13 Oct 2023
We are pleased to share that the EMA (European Medicines Agency) has recommended the approval of Vamorolone – the first ever treatment for all patients with Duchenne. Vamorolone is an alternative to corticosteroids. It was developed with the aim of maximising...
1 Jul 2023
It has been a busy time in the Duchenne arena. In the US, the FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world, and represents a very exciting step...
22 Jun 2023
Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals...